| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three months and nine months ended August 31, 2021 and August 31, 2020:
|
|
|
For the three
months ended
August 31,
2021
|
|
|
For the three
months ended
August 31,
2020
|
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
7,326,516
|
|
|
$
|
7,914,732
|
|
|
PrepaCyte®-CB
|
|
|
18,200
|
|
|
|
82,800
|
|
|
Public cord blood banking
|
|
|
158,936
|
|
|
|
116,826
|
|
|
Total net revenue
|
|
$
|
7,503,652
|
|
|
$
|
8,114,358
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,943,419
|
|
|
$
|
1,911,141
|
|
|
PrepaCyte®-CB
|
|
|
53,498
|
|
|
|
55,021
|
|
|
Public cord blood banking
|
|
|
462,021
|
|
|
|
394,162
|
|
|
Total cost of sales
|
|
$
|
2,458,938
|
|
|
$
|
2,360,324
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
262,229
|
|
|
$
|
35,616
|
|
|
PrepaCyte®-CB
|
|
|
6,894
|
|
|
|
6,894
|
|
|
Public cord blood banking
|
|
|
359
|
|
|
|
—
|
|
|
Total depreciation and amortization
|
|
$
|
269,482
|
|
|
$
|
42,510
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,941,976
|
|
|
$
|
2,736,798
|
|
|
PrepaCyte®-CB
|
|
|
(42,193
|
)
|
|
|
21,291
|
|
|
Public cord blood banking
|
|
|
(303,445
|
)
|
|
|
(277,868
|
)
|
|
Total operating income
|
|
$
|
1,596,338
|
|
|
$
|
2,480,221
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
335,870
|
|
|
$
|
338,675
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total interest expense
|
|
$
|
335,870
|
|
|
$
|
338,675
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the nine
months ended
August 31,
2021
|
|
|
For the nine
months ended
August 31,
2020
|
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
21,224,033
|
|
|
$
|
22,921,922
|
|
|
PrepaCyte®-CB
|
|
|
56,200
|
|
|
|
200,507
|
|
|
Public cord blood banking
|
|
|
289,231
|
|
|
|
484,547
|
|
|
Total net revenue
|
|
$
|
21,569,464
|
|
|
$
|
23,606,976
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
5,453,203
|
|
|
$
|
5,932,655
|
|
|
PrepaCyte®-CB
|
|
|
129,581
|
|
|
|
128,154
|
|
|
Public cord blood banking
|
|
|
1,111,022
|
|
|
|
1,283,202
|
|
|
Total cost of sales
|
|
$
|
6,693,806
|
|
|
$
|
7,344,011
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
536,823
|
|
|
$
|
109,351
|
|
|
PrepaCyte®-CB
|
|
|
20,683
|
|
|
|
20,683
|
|
|
Public cord blood banking
|
|
|
661
|
|
|
|
—
|
|
|
Total depreciation and amortization
|
|
$
|
558,167
|
|
|
$
|
130,034
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
5,743,184
|
|
|
$
|
6,229,222
|
|
|
PrepaCyte®-CB
|
|
|
(94,065
|
)
|
|
|
51,671
|
|
|
Public cord blood banking
|
|
|
(822,452
|
)
|
|
|
(799,416
|
)
|
|
Total operating income
|
|
$
|
4,826,667
|
|
|
$
|
5,481,477
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
957,479
|
|
|
$
|
1,069,345
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total interest expense
|
|
$
|
957,479
|
|
|
$
|
1,069,345
|
|
|
|
|
|
|
|
|
|
|
|
The following table shows the assets by segment as of August 31, 2021 and November 30, 2020:
|
|
|
As of
August 31,
2021
|
|
|
As of
November 30,
2020
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
47,637,754
|
|
|
$
|
34,215,780
|
|
|
PrepaCyte®-CB
|
|
|
243,312
|
|
|
|
302,683
|
|
|
Public cord blood banking
|
|
|
11,542,964
|
|
|
|
11,681,631
|
|
|
Total assets
|
|
$
|
59,424,030
|
|
|
$
|
46,200,094
|
|
|